Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 12, 2010
Event: Unregistered Sales of Equity Securities (Item 3.02)
Key Financial Metrics
This filing details a capital raise and debt conversion rather than standard operating performance metrics. Revenue, profit, cash flow, and operating margins are not reported in this document.
- Total Debt Converted: $2,517,660 (unpaid principal and interest on ten promissory notes).
- Original Note Principal: $2,450,000.
- Units Issued for Debt Conversion: 1,258,830 Units.
- Cash Raised from New Investors: $800,000 total.
- September 30, 2010: $300,000 for 150,000 Units.
- October 1, 2010: $500,000 for 250,000 Units.
- Price per Unit: $2.00.
Material Changes
The Company amended the terms of ten outstanding promissory notes, converting the total unpaid balance of $2,517,660 into equity. This transaction reduced the Company's debt load and increased its equity capitalization.
Additionally, the Company issued 400,000 new Units to accredited investors for cash consideration, increasing liquidity.
Offering Structure and Management Commentary
The transaction was conducted under Rule 506 of the Securities Act of 1933. Each "Unit" issued consists of:
- One share of Common Stock (par value $0.001).
- One two-year Class D Warrant to purchase one share of Common Stock at an exercise price of $2.00.
- One Option expiring December 31, 2010, to purchase the same number of Units at $2.00 per Unit.
Related Party Transaction: Kevin A. Richardson II, Chairman of the Board, was one of the noteholders who converted notes in this Offering.
Risks/Contingencies: The filing does not explicitly list new risks, though the issuance of warrants and options creates potential future dilution. The filing text does not provide a clear value for the Company's current cash balance or liquidity position post-transaction.
Investor Verification Checklist
- Verify the total number of shares outstanding post-conversion to assess dilution impact.
- Confirm the status of the Options expiring December 31, 2010, and the likelihood of exercise.
- Review the Company's most recent 10-K or 10-Q to determine the impact of the $800,000 cash infusion on working capital.
- Check for any subsequent filings regarding the exercise of the Class D Warrants.